Search
Centessa Pharmaceuticals PLC
CNTAAdd to Watchlist
40.500USD
0.0000.00%
Market hours （ET）Quotes delayed by 15 min
6.27BMarket Cap
LossP/E TTM
More Details of Centessa Pharmaceuticals PLC Company
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Centessa Pharmaceuticals PLC Info
Ticker SymbolCNTA
Company nameCentessa Pharmaceuticals PLC
IPO dateMay 28, 2021
CEOSaha (Saurabh)
Number of employees77
Security typeDepository Receipt
Fiscal year-endMay 28
Address3rd Floor
CityALTRINCHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeWA14 2DT
Phone447391789784
Websitehttps://www.centessa.com/
Ticker SymbolCNTA
IPO dateMay 28, 2021
CEOSaha (Saurabh)
Company Executives of Centessa Pharmaceuticals PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Arjun Goyal, M.D.
Dr. Arjun Goyal, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
462.58K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
91.08K
+50.41%
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
3.89K
-1882.61%
Mr. Iqbal Hussain
Mr. Iqbal Hussain
General Counsel and Chief Compliance Officer, Company Secretary
General Counsel and Chief Compliance Officer, Company Secretary
--
--
Ms. Tia Bush
Ms. Tia Bush
Chief Technology and Quality Officer
Chief Technology and Quality Officer
--
--
Dr. Francesco de Rubertis, Ph.D.
Dr. Francesco de Rubertis, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Brett I. W. Zbar, M.D.
Dr. Brett I. W. Zbar, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mary Lynne Hedley, Ph.D.
Dr. Mary Lynne Hedley, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Carol Stuckley
Ms. Carol Stuckley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Arjun Goyal, M.D.
Dr. Arjun Goyal, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
462.58K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
91.08K
+50.41%
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
3.89K
-1882.61%
Mr. Iqbal Hussain
Mr. Iqbal Hussain
General Counsel and Chief Compliance Officer, Company Secretary
General Counsel and Chief Compliance Officer, Company Secretary
--
--
Ms. Tia Bush
Ms. Tia Bush
Chief Technology and Quality Officer
Chief Technology and Quality Officer
--
--
Dr. Francesco de Rubertis, Ph.D.
Dr. Francesco de Rubertis, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
FAQs
Who are the top five shareholders of Centessa Pharmaceuticals PLC?
The top five shareholders of Centessa Pharmaceuticals PLC are: Dr. Arjun Goyal, M.D.
How many institutions hold shares of Centessa Pharmaceuticals PLC (CNTA)?
As of 2026Q1, 276 institutions hold shares of Centessa Pharmaceuticals PLC, with a combined market value of approximately 150.25M, accounting for 97.10% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 12002120.00.
